These FTSE 100 stocks sank in October. Time to stock up?

Royston Wild runs the rule over two recent FTSE 100 (INDEXFTSE: UKX) losers.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

While the unpredictable nature of drugs development doesn’t guarantee a much-awaited earnings bounce at AstraZeneca (LSE: AZN), I believe the firm’s transformed product pipeline makes it a hot stock for growth candidates.

The post-Brexit stampede towards AstraZeneca ground to a shuddering halt in October, the stock shedding 8% of its value.

The Cambridge company suffered as US regulators had halted testing of its Durvalumab cancer battler due to concerns over bleeding. News that its Brilinta drug didn’t demonstrate benefits compared with older cardiovascular treatment Copidogrel did the stock no favours either.

But October wasn’t a complete washout on the R&D front, with AstraZeneca reporting “a clinically-meaningful and statistically-significant improvement of progression-free survival” for those using Lynparza in Phase III trials. The drug is used to treat ovarian cancer and has been identified as a potential sales driver in the years ahead.

The City expects AstraZeneca to swallow earnings dips of 4% in both 2016 and 2017. But subsequent P/E ratings of 13.5 times and 14 times represent a great level for long-term investors to latch onto the firm, in my opinion, as rising healthcare investment looks likely to power demand for the pharma giant’s next generation of drugs.

On top of this, expectations that AstraZeneca will keep the dividend locked at 280 US cents per share mean it yields a stunning 4.8%. I reckon the drugs leviathan is a terrific pick at current prices.

Gold star

Precious metals giant Randgold Resources (LSE: RRS) also took a share price hit last month. The stock shed 7% of its value during October, pressured by gold values sinking back below the $1,300 per ounce landmark to their cheapest since June.

Investors have traded out of the metal in recent weeks as a steady stream of upbeat US economic datasets have boosted expectations of a Federal Reserve hike. Indeed, last week’s blockbuster GDP numbers will prove the precursor to Janet Yellen hitting the button as soon as December, or so say a large number of market commentators.

But while the safe-haven commodity may have lost a little of its lustre, values have stabilised around $1,270 more recently, and with good reason.

There’s still plenty of tension surrounding the potential outcome of the US presidential election, not to mention the prospect of long and difficult Brexit negotiations that could send gold prices northwards again. And shiny metal values could also rise should global trade indicators continue to deteriorate in the months ahead.

Meanwhile, Randgold is laying the groundwork for stellar earnings growth in the years ahead as it increases output at its top-quality assets in the Côte d’Ivoire and Democratic Republic of Congo.

The number crunchers expect Randgold to enjoy earnings surges of 50% and 33% in 2016 and 2017 respectively. Consequent P/E ratios of 29.7 times and 22.3 times may appear toppy on paper, although PEG ratios of 0.6 times through to the close of 2017 suggest the FTSE 100 digger isn’t that expensive based on its predicted earnings trajectory.

I reckon there’s still plenty of fuel in the system that could send Randgold’s share price rocketing higher again.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »